Tigress Financial initiated coverage of IFF (IFF) with a Buy rating and $105 price target IFF is strategically positioned for long-term growth by capitalizing on the rising consumer demand for health-oriented and functional products, targeted investments, and a broad product portfolio, combined with its ongoing focus on R&D-driven opportunities and balance sheet and product portfolio optimization, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFF:
- Positive Outlook for IFF: Buy Rating Supported by Stability and Growth Potential
- Icahn boosts stakes in CVR Partners, JetBlue, Illumina
- IFF price target lowered to $98 from $100 at Morgan Stanley
- Strong Growth Potential and Attractive Valuation Make International Flavors & Fragrances a Compelling Investment
- Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls